Loading...
XSWX
PPGN
Market cap1.02bUSD
Dec 05, Last price  
24.75CHF
1D
-1.00%
1Q
-4.81%
IPO
-69.16%
Name

PolyPeptide Group AG

Chart & Performance

D1W1MN
XSWX:PPGN chart
P/E
—
P/S
2.57
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.92%
Rev. gr., 5y
10.82%
Revenues
339m
+5.72%
179,574,000202,613,000224,296,000282,126,000280,978,000320,372,000338,688,000
Net income
-20m
L-61.97%
23,820,00025,737,00031,335,00047,258,0007,767,000-51,440,000-19,564,000
CFO
89m
+145.03%
22,943,00055,600,00049,482,00057,352,0005,460,00036,485,00089,399,000
Dividend
Apr 28, 20220.3 CHF/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
URL
https://www.polypeptide.com/
IPO date
Apr 29, 2021
Employees
1,181
Domiciled in
CH
Incorporated in
CH

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT